Literature DB >> 3059669

A critical look at the importance, prevalence and control of toxocariasis and the possibilities of immunological control.

O O Barriga1.   

Abstract

The visceral infection of humans with Toxocara canis is particularly prevalent in children and may cause a variety of symptoms that commonly persist for 6-24 months. The ocular infection usually causes permanent loss of visual acuity. Human infection is acquired by ingestion of embryonated T. canis eggs with contaminated dirt. Review of recent reports indicates that patent T. canis infection is widely prevalent in the general population of dogs all over the world (3-81%) and results in a substantial contamination of the ground (0.3-87%). The results of sensitive and specific serological tests suggest that about 7% of the clinically healthy human population of the United States, about 5% of that of Canada, and about 4% of that in Great Britain is infected with the parasite. Control of transmission of the parasite to man is often attempted by eliminating the infection in dogs, reducing the population of dogs and the environmental contamination with their feces, and educating the public about the zoonotic potential of toxocariasis. The evidence reviewed indicates that these methods are only marginally effective. Because T. canis relies on congenital and lactogenic transmission to persist in nature, only a procedure that effects the sustained killing of the reservoir larvae in the tissues of the bitch, or of newly-acquired parasites, is expected to be successful. Research with mice, rabbits and dogs demonstrated that prior infections of the host induce the development of protective immunity to reinfections. This procedure, however, leaves remnant populations of larvae from the immunizing infections that are resistant to anthelmintics and to the effect of prior irradiation. Hyperimmunization with partially-purified extracts of T. canis larvae induced 37% resistance to a challenge in mice when the extract was administered alone, and 76% resistance when administered with lipopolysaccharide adjuvant. Production of complete resistance, however, will probably require the prior control of the immunosuppression induced by the parasite. T. canis infections inhibit the production of homologous protective immunity and antibody responses to heterologous antigens, probably by interfering with the activity of helper T-cells, competing with protective antigens, and suppressing antibody synthesis. The evidence indicates, however, that an anti-T. canis vaccine to eliminate the parasite in dogs is feasible.

Entities:  

Mesh:

Year:  1988        PMID: 3059669     DOI: 10.1016/0304-4017(88)90126-4

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  22 in total

1.  An alternative method for producing Toxocara canis second stage larvae from a paratenic host (pigeon) for mRNA extraction purpose.

Authors:  Amir Rahbar; Alireza Alborzi; Masoudreza Seifi Abad Shapoori
Journal:  J Parasit Dis       Date:  2013-06-07

Review 2.  Cerebral Toxocariasis: Silent Progression to Neurodegenerative Disorders?

Authors:  Chia-Kwung Fan; Celia V Holland; Karen Loxton; Ursula Barghouth
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 3.  Highlights of human toxocariasis.

Authors:  J F Magnaval; L T Glickman; P Dorchies; B Morassin
Journal:  Korean J Parasitol       Date:  2001-03       Impact factor: 1.341

4.  Differences in the clinical and radiological characteristics of lung-involved toxocariasis between toxocariasis with eosinophilia and those without eosinophilia.

Authors:  Bo Mi Park; Sang Ok Jeong; Hee Sun Park; Sung Soo Jung; Sun Young Kim; Ju Ock Kim; Jeong Eun Lee
Journal:  J Thorac Dis       Date:  2014-12       Impact factor: 2.895

5.  MRI in cerebral toxocaral disease.

Authors:  P Rüttinger; H Hadidi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-04       Impact factor: 10.154

6.  Toxocara spp. seroprevalence in sheep from southern Brazil.

Authors:  Gabriela Lopes Rassier; Sibele Borsuk; Felipe Pappen; Carlos Jaime Scaini; Tiago Gallina; Marcos Marreiro Villela; Nara Amélia da Rosa Farias; Magda Vieira Benavides; Maria Elisabeth Aires Berne
Journal:  Parasitol Res       Date:  2013-07-07       Impact factor: 2.289

7.  Epidemiologic approach to human toxocariasis in western France.

Authors:  B Gueglio; L de Gentile; J M Nguyen; J Achard; D Chabasse; M Marjolet
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

8.  Inhibition of lymphoproliferative response and its restoration with a glucan immunomodulator in mice with experimental larval toxocarosis.

Authors:  Z Borosková; K Reiterová; P Dubinský; O Tomasovicová; B Machnicka
Journal:  Folia Microbiol (Praha)       Date:  1998       Impact factor: 2.099

9.  Endoparasite prevalence and recurrence across different age groups of dogs and cats.

Authors:  Maureen C Gates; Thomas J Nolan
Journal:  Vet Parasitol       Date:  2009-08-03       Impact factor: 2.738

10.  Zoonotic infections in communities of the James Bay Cree territory: An overview of seroprevalence.

Authors:  Hugues Sampasa-Kanyinga; Benoit Lévesque; Elhadji Anassour-Laouan-Sidi; Suzanne Côté; Bouchra Serhir; Brian J Ward; Michael D Libman; Michael A Drebot; Kai Makowski; Kristina Dimitrova; Momar Ndao; Eric Dewailly
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.